{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T21:21:42Z","timestamp":1783027302715,"version":"3.54.6"},"reference-count":28,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,4]],"date-time":"2026-04-04T00:00:00Z","timestamp":1775260800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100014848","name":"Arnold Ventures LLC","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014848","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Cancer Policy"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.jcpo.2026.100736","type":"journal-article","created":{"date-parts":[[2026,4,4]],"date-time":"2026-04-04T15:21:34Z","timestamp":1775316094000},"page":"100736","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Evolving challenges in smoldering myeloma trials: shifting endpoint measurement and definitions"],"prefix":"10.1016","volume":"48","author":[{"given":"Myung Sun","family":"Kim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vinay","family":"Prasad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6936-5783","authenticated-orcid":false,"given":"Timoth\u00e9e","family":"Olivier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jcpo.2026.100736_bib1","unstructured":"https:\/\/www.jnj.com\/media-center\/press-releases\/european-commission-approves-darzalex-daratumumab-as-the-first-licensed-treatment-for-patients-with-high-risk-smouldering-multiple-myeloma. Accessed April 10, 2026."},{"key":"10.1016\/j.jcpo.2026.100736_bib2","unstructured":"https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-daratumumab-and-hyaluronidase-fihj-high-risk-smoldering-multiple-myeloma. Accessed April 10, 2026."},{"key":"10.1016\/j.jcpo.2026.100736_bib3","unstructured":"National Comprehensive Cancer Network. Multiple Myeloma (Version 2.2026).\u3008https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/myeloma.pdf\u3009. Accessed July 19, 2025."},{"issue":"18","key":"10.1016\/j.jcpo.2026.100736_bib4","doi-asserted-by":"crossref","first-page":"1777","DOI":"10.1056\/NEJMoa2409029","article-title":"Daratumumab or active monitoring for high-risk smoldering multiple myeloma","volume":"392","author":"Dimopoulos","year":"2025","journal-title":"N. Engl. J. Med."},{"issue":"11","key":"10.1016\/j.jcpo.2026.100736_bib5","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1200\/JCO.19.01740","article-title":"Randomized trial of lenalidomide versus observation in smoldering multiple myeloma","volume":"38","author":"Lonial","year":"2020","journal-title":"J. Clin. Oncol."},{"issue":"5","key":"10.1016\/j.jcpo.2026.100736_bib6","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1056\/NEJMoa1300439","article-title":"Lenalidomide plus dexamethasone for high-risk smoldering multiple myeloma","volume":"369","author":"Mateos","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jcpo.2026.100736_bib7","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.ejca.2022.07.030","article-title":"Lenalidomide-dexamethasone versus observation in high-risk smoldering myeloma after 12 years of median follow-up time: A randomized, open-label study","volume":"174","author":"Mateos","year":"2022","journal-title":"Eur. J. Cancer"},{"issue":"10","key":"10.1016\/j.jcpo.2026.100736_bib8","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1200\/JCO.2011.38.7571","article-title":"Progression-free survival: meaningful or simply measurable?","volume":"30","author":"Booth","year":"2012","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.jcpo.2026.100736_bib9","article-title":"Bedside implications of the use of surrogate endpoints in solid and haematological cancers: implications for our reliance on PFS, DFS, ORR, MRD and more","volume":"3","author":"Olivier","year":"2024","journal-title":"BMJ Oncol."},{"issue":"12","key":"10.1016\/j.jcpo.2026.100736_bib10","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1038\/s41571-023-00823-5","article-title":"Progression-free survival, disease-free survival and other composite end points in oncology: improved reporting is needed","volume":"20","author":"Walia","year":"2023","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"4","key":"10.1016\/j.jcpo.2026.100736_bib11","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1038\/leu.2012.296","article-title":"Serum free light chain ratio as a biomarker for high-risk smoldering multiple myeloma","volume":"27","author":"Larsen","year":"2013","journal-title":"Leukemia"},{"issue":"5","key":"10.1016\/j.jcpo.2026.100736_bib12","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1056\/NEJMc1106428","article-title":"Diagnosis of smoldering multiple myeloma","volume":"365","author":"Rajkumar","year":"2011","journal-title":"N. Engl. J. Med."},{"issue":"9","key":"10.1016\/j.jcpo.2026.100736_bib13","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1200\/JCO.2009.25.5356","article-title":"Prognostic significance of focal lesions in whole-body magnetic resonance imaging in patients with asymptomatic multiple myeloma","volume":"28","author":"Hillengass","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.jcpo.2026.100736_bib14","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2023.101910","article-title":"SLiM CRAB criteria revisited: temporal trends in prognosis of patients with smoldering multiple myeloma who meet the definition of \u2018biomarker-defined early multiple myeloma\u2019\u2014a systematic review with meta-analysis","volume":"58","author":"Ludwig","year":"2023","journal-title":"eClinicalMedicine"},{"issue":"13","key":"10.1016\/j.jcpo.2026.100736_bib15","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1182\/blood.2025031907","article-title":"Time to revise myeloma diagnostic criteria? A decade of accumulated evidence on a serum free light chain ratio of \u2265100","volume":"147","author":"Chakraborty","year":"2026","journal-title":"Blood"},{"issue":"282","key":"10.1016\/j.jcpo.2026.100736_bib16","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1080\/01621459.1958.10501452","article-title":"Nonparametric estimation from incomplete observations","volume":"53","author":"Kaplan","year":"1958","journal-title":"J. Am. Stat. Assoc."},{"issue":"1","key":"10.1016\/j.jcpo.2026.100736_bib17","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1186\/s12874-021-01308-8","article-title":"IPDfromKM: reconstruct individual patient data from published Kaplan-Meier survival curves","volume":"21","author":"Liu","year":"2021","journal-title":"BMC Med. Res. Methodol."},{"issue":"6","key":"10.1016\/j.jcpo.2026.100736_bib18","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1016\/S1470-2045(24)00722-8","article-title":"The BREAKING-ICE App: an interactive journey into informative censoring","volume":"26","author":"Olivier","year":"2025","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.jcpo.2026.100736_bib19","unstructured":"\u3008https:\/\/www.timotheeolivier-research.com\/breaking-ice\u3009, select \"AQUILA-OS\" or \"AQUILA-PFS. Updated June 7, 2025. Accessed July 17, 2025."},{"issue":"17","key":"10.1016\/j.jcpo.2026.100736_bib20","doi-asserted-by":"crossref","first-page":"2203","DOI":"10.1001\/jama.294.17.2203","article-title":"Randomized Trials Stopped Early for Benefit A Systematic Review","volume":"294","author":"Montori","year":"2005","journal-title":"JAMA"},{"key":"10.1016\/j.jcpo.2026.100736_bib21","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2025.115702","article-title":"When suboptimal post-protocol care in oncology trials is rewarded","volume":"228","author":"Salfi","year":"2025","journal-title":"Eur. J. Cancer"},{"issue":"1","key":"10.1016\/j.jcpo.2026.100736_bib22","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1186\/s12885-023-10917-z","article-title":"Post-progression treatment in cancer randomized trials: a cross-sectional study of trials leading to FDA approval and published trials between 2018 and 2020","volume":"23","author":"Olivier","year":"2023","journal-title":"BMC Cancer"},{"key":"10.1016\/j.jcpo.2026.100736_bib23","unstructured":"https:\/\/www.iqwig.de\/download\/a25-109_daratumumab_nutzenbewertung-35a-sgb-v_v1-0.pdf. Accessed April 10, 2026."},{"issue":"6","key":"10.1016\/j.jcpo.2026.100736_bib24","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1016\/S1470-2045(23)00165-1","article-title":"Review of the monarchE trial suggests no evidence to support use of adjuvant abemaciclib in women with breast cancer","volume":"24","author":"Meirson","year":"2023","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.jcpo.2026.100736_bib25","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2024.114192","article-title":"CDK4\/6 inhibitors as adjuvant therapy in early breast cancer? Uncertain benefits, guaranteed harms","volume":"207","author":"Haslam","year":"2024","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.jcpo.2026.100736_bib26","article-title":"Prevalence and prognosis of patients with breast cancer eligible for adjuvant abemaciclib or ribociclib: a nationwide population-based study","volume":"59","author":"Liu","year":"2025","journal-title":"Lancet Reg. Health Eur."},{"issue":"35","key":"10.1016\/j.jcpo.2026.100736_bib27","doi-asserted-by":"crossref","first-page":"3691","DOI":"10.1200\/JCO-25-01440","article-title":"Defense of adjuvant CDK4\/6 inhibitors in early breast cancer","volume":"43","author":"De Laurentiis","year":"2025","journal-title":"J. Clin. Oncol."},{"issue":"22","key":"10.1016\/j.jcpo.2026.100736_bib28","doi-asserted-by":"crossref","first-page":"2456","DOI":"10.1200\/JCO-24-02683","article-title":"Why we do not recommend that women with breast cancer receive adjuvant treatment with a CDK4\/6 inhibitor","volume":"43","author":"Tannock","year":"2025","journal-title":"J. Clin. Oncol."}],"container-title":["Journal of Cancer Policy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213538326000378?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213538326000378?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T20:49:41Z","timestamp":1783025381000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2213538326000378"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":28,"alternative-id":["S2213538326000378"],"URL":"https:\/\/doi.org\/10.1016\/j.jcpo.2026.100736","relation":{},"ISSN":["2213-5383"],"issn-type":[{"value":"2213-5383","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Evolving challenges in smoldering myeloma trials: shifting endpoint measurement and definitions","name":"articletitle","label":"Article Title"},{"value":"Journal of Cancer Policy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jcpo.2026.100736","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"100736"}}